Study Results Champion Keytruda/Chemo as ‘New Standard of Care’ in TNBC Subset
The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.
Read More
CAR-T Cell Therapy Bests Standard of Care in Health-Related Quality of Life for Patients With Lymphoma
Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.
New Agent Can Improve BCG Response, Quality of Life in Bladder Cancer
The novel drug N-803 boosted response to Bacille Calmette-Guérin therapy in patients with non-muscle invasive bladder cancer, a study showed.
Novel BTK Inhibitor Well Tolerated in Patients with CLL, Other B-Cell Malignancies
TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.
MCL Treatment: Differences Exist Between Trial-Based Recommendations and Real-World Care
Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.
Adding Lynparza to Avastin Significantly Improves Survival in Ovarian Cancer
Maintenance treatment with Lynparza plus Avastin over Avastin alone provided a certain group of patients with ovarian cancer a substantial survival benefit.
Lynparza Following Standard of Care Treatments Effective in Some Patients with High-Risk Breast Cancer
Some patients with early HER2-negative breast cancer at high risk for disease recurrence achieved meaningful benefit with Lynparza after receiving standard of care therapies, such as surgery or chemotherapy.
Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
